Trial reportThe American journal of tropical medicine and hygiene2009
Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep.
Trial report in The American journal of tropical medicine and hygiene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review.The American journal of tropical medicine and hygiene · 2011Trial
- Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: a randomized clinical trial in naturally infected sheep.PLoS neglected tropical diseases · 2010Trial
- Exploitation of nanocrystal suspension as an effective oral formulation for oxfendazole.Drug delivery and translational research · 2022Article
- Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice.Parasitology · 2020Article
- Nanostructured lipid carriers of ivermectin as a novel drug delivery system in hydatidosis.Parasites & vectors · 2019Article
- Osseous cystic echinococcosis: A case series study at a referral unit in Spain.PLoS neglected tropical diseases · 2019Article
- Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.Expert review of anti-infective therapy · 2019Review
- Shortage of Albendazole and Its Consequences for Patients with Cystic Echinococcosis Treated at a Referral Center in Italy.The American journal of tropical medicine and hygiene · 2018Article
- Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets.PLoS neglected tropical diseases · 2018Article
- In vivo and in vitro efficacies of mebendazole, mefloquine and nitazoxanide against cyst echinococcosis.Parasitology research · 2015Article
- Pulmonary cystic echinococcosis.Current opinion in pulmonary medicine · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
Abstract
Cystic echinococosis (CE) is a public health problem caused by Echinococcus granulosus. We aimed to determine the efficacy of nitazoxanide (NTZ) and oxfendazole (OXF) against CE in naturally infected sheep. A total of 151 ewes were assigned to the following groups: 15 mg/kg of NTZ weekly for five weeks (NTZ5); two rounds of 15 mg/ kg of NTZ a day for five days (NTZ5x2) two weeks apart; 30 mg/kg of OXF a week for 11 weeks (OXF11); 30 mg/kg of OXF plus 15 mg/kg of NTZ a week for 11 weeks (OXF/NTZ); and the control group. OXF11 and OXF/NTZ decreased the number of fertile cysts, increased the number of degenerated cysts, and were more efficacious (49.6-61.2%) against lung cysts and liver cysts (91.8-100%) than any other treatment group. OXF might be an additional strategy for control programs and an optional treatment of human CE after it is licensed.
Indexed as
Identifiers
19270283PMC2673094W2127591583What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.